搜索范围
32097
应用筛选条件
关键词:'32097'
显示 1-30 #N/A 45 条结果 关于 "32097" 范围 论文
Peter Lierz et al.
Acta orthopaedica, 83(6), 642-647 (2012-11-13)
BACKGROUND AND PURPOSE Analgesics can have undesirable effects. We assessed whether a single preoperative dose of 120 mg etoricoxib reduces the need for additional opioids after therapeutic arthroscopic knee surgery. METHODS A double-blind, placebo-controlled study was performed at a single
Deborah J Cochrane et al.
Drugs, 62(18), 2637-2651 (2002-12-06)
Etoricoxib is a cyclo-oxygenase (COX)-2-selective NSAID with a higher COX-1 to COX-2 selectivity ratio than the other COX-2-selective NSAIDs rofecoxib, valdecoxib or celecoxib. In patients with rheumatoid arthritis, improvements in tender and swollen joint counts and patient and investigator global
Sanjiv Kumar et al.
Acta poloniae pharmaceutica, 68(6), 839-843 (2011-12-01)
A simple, reproducible and efficient reverse phase high performance liquid chromatographic method was developed for simultaneous estimation of etoricoxib and thiocolchicoside in combined tablet dosage form. Formulation containing etoricoxib and thiocolchicoside is used as analgesic. Chromatography was performed on a
Klaus Schaffler et al.
British journal of clinical pharmacology, 75(2), 404-414 (2012-07-11)
Laser (radiant-heat) evoked potentials (LEPs) from vertex-EEG peak-to-peak (PtP) amplitude were used to determine acute antinociceptive/antihyperalgesic efficacy of ABT-102, a novel TRPV1 antagonist efficacious in preclinical pain models, compared with active controls and placebo in normal and UV(B)-inflamed skin. This
Shruti Setia et al.
Molecular and cellular biochemistry, 369(1-2), 75-86 (2012-07-04)
Non-steroidal anti-inflammatory drugs (NSAIDs) are emerging as novel chemopreventive agents against a variety of cancers owing to their capability in blocking the tumor development by cellular proliferation, angiogenesis and by promoting apoptosis. The present study further explored the comparative role
Rita Citraro et al.
Brain research bulletin, 113, 1-7 (2015-02-24)
Different data suggest the involvement of specific inflammatory pathways in the pathogenesis of epilepsy. Cyclooxygenase (COX), which catalyses the production of pro-inflammatory prostaglandins, may play a significant role in seizure-induced neuroinflammation and neuronal hyperexcitability. COX-2 is constitutively expressed in the
L I Alekseeva
Terapevticheskii arkhiv, 82(8), 57-62 (2010-09-29)
The review gives and analyzes the data of a number of studies evaluating the safety and efficacy of nonsteroidal anti-inflammatory drugs on the upper gastrointestinal tract. Particular emphasis is laid on the results of the multinational etoricoxib and diclofenac arthritis
Beate Mayer et al.
Transfusion, 53(5), 1033-1036 (2012-08-14)
Etoricoxib, a selective inhibitor of cyclooxygenase 2, is increasingly used in pain relief. Here, we report the first case of etoricoxib-induced immune hemolytic anemia. An 84-year-old male patient developed anemia 1 week after treatment with etoricoxib. There was no evidence
Shashi Srivastava et al.
Middle East journal of anaesthesiology, 21(5), 725-730 (2012-12-26)
Etoricoxib, a selective Cox-2 inhibitor has been found to be effective in the management of acute pain. This study evaluates the effect of preoperative use of oral Etoricoxib on post operative pain relief and sleep in patients undergoing single level
[Effective pain management after hallux valgus correction].
Elke Mertens
Pflege Zeitschrift, 65(6), 339-339 (2012-06-30)
M Hasanuzzaman Shohag et al.
Arzneimittel-Forschung, 61(11), 617-621 (2012-01-12)
The aim of this study was to compare the pharmacokinetic properties of two etoricoxib (CAS 202409-33-4) 60 mg formulations, namely Etocox-60 (test product) and reference product, and to evaluate whether these two formulations meet the FDA criteria to assume bioequivalence.
Shaunta' D Martina et al.
The Annals of pharmacotherapy, 39(5), 854-862 (2005-04-14)
To review the available literature evaluating the pharmacology, pharmacokinetics, clinical efficacy, and adverse effects of etoricoxib, a highly selective cyclooxygenase-2 (COX-2) inhibitor that is not currently approved for use in the US. Literature retrieval was accessed through MEDLINE (1966-December 2004)
Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.
Chen YF
Health Technology Assessment (Winchester, England), 12(11), 1-278 (2008)
Shruti Setia et al.
Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer, 31(1), 27-37 (2012-05-18)
9,10-Dimethyl benz(a)anthracene (DMBA), when injected intratracheally once at a dose of 20 mg/kg body weight, is found to induce lung cancer in rats. Two nonsteroidal anti-inflammatory drugs (NSAIDs), indomethacin and etoricoxib, are given orally daily as chemopreventive agents at a
Bahadir Suleyman et al.
International immunopharmacology, 23(1), 179-185 (2014-07-30)
The purpose of this study was to investigate the effect of etoricoxib on oxidative injury induced with ischemia-reperfusion (I/R) in rat kidney tissue in terms of biochemistry and immunohistochemistry. Male Albino Wistar rats were divided into renal I/R (RIR), 50
Lisa Zimmer et al.
Archives of dermatology, 148(3), 357-361 (2012-01-18)
Painful lobular panniculitis appears to be a novel cutaneous adverse effect of selective BRAF inhibitors. We report the clinical course and management in 2 women with metastatic melanomas harboring the BRAF(V600E) mutation, who developed panniculitis with arthralgia during therapy with
Neeti Nadda et al.
Molecular and cellular biochemistry, 372(1-2), 101-112 (2012-09-20)
This study explored the role of pro- and anti-inflammatory cytokines in dimethyl benz(a)anthracene (DMBA)-induced lung cancer and its subsequent correction with a COX-2 inhibitory NSAID, etoricoxib. A single dose of DMBA (20 mg/kg body weight) in 0.9 % NaCl administered
Shruti Setia et al.
Molecular and cellular biochemistry, 366(1-2), 89-99 (2012-03-14)
Roles of cyclooxygenase (COX) enzyme and intrinsic pathway of apoptosis have been explored for the chemopreventive effects of non-steroidal anti-inflammatory drugs (NSAIDs) on 9,10-dimethyl benz(a)anthracene (DMBA)-induced lung cancer in rat model. 16 weeks after the administration of DMBA, morphological analysis
B Renner et al.
European journal of pain (London, England), 16(6), 838-848 (2012-02-18)
Administering cyclooxygenase-2 inhibitors preoperatively appears attractive since these drugs reduce post-operative pain, but do not increase the risk of post-operative bleeds, asthmatic attacks and stress-related gastrointestinal ulcers. In a former investigation, we could show that post-operative administration of etoricoxib reduces
I L Meek et al.
European journal of clinical pharmacology, 69(3), 365-371 (2012-08-15)
Nonsteroidal anti-inflammatory drugs (NSAIDs) and acetylsalicylic acid (ASA) are often prescribed concurrently in patients with nociceptive pain and cardiovascular comorbidity. NSAIDs and ASA inhibit the same COX-enzymes, and thus may interact. ASA's cardioprotective antiplatelet effect is entirely COX-1 dependent. NSAIDs
V Dahl et al.
Acta anaesthesiologica Scandinavica, 56(1), 95-101 (2011-11-23)
Many studies have demonstrated that either COX-2 antagonists or glucocorticoids are efficient analgesics after orthopaedic surgery. We wanted to evaluate if the combination of these two drugs was better than one drug alone when added to paracetamol, local anaesthesia, and
Jody K Takemoto et al.
Clinical pharmacokinetics, 47(11), 703-720 (2008-10-09)
The NSAID etoricoxib is a selective inhibitor of cyclo-oxygenase 2 (COX-2), approved for treatment of patients with chronic arthropathies and musculoskeletal and dental pain. The rate of absorption of etoricoxib is moderate when given orally (the maximum plasma drug concentration
Rachel Clarke et al.
The Cochrane database of systematic reviews, 4(4), CD004309-CD004309 (2012-04-20)
Etoricoxib is a selective cyclo-oxygenase-2 (COX-2) inhibitor licensed for the relief of chronic pain in osteoarthritis and rheumatoid arthritis, and acute pain in some jurisdictions. This class of drugs is believed to be associated with fewer upper gastrointestinal adverse effects
M A Radwan et al.
Arzneimittel-Forschung, 62(7), 313-318 (2012-05-03)
The effect of chronic administration of etoricoxib (EXB), in the absence or presence of St. John's Wort (SJW), on its pharmacokinetic parameters and blood pressure was investigated in rats.Rats were divided into 3 groups, each group received daily different oral
Rik J Lories
Expert opinion on drug metabolism & toxicology, 8(12), 1599-1608 (2012-11-07)
Nonsteroidal anti-inflammatory drugs (NSAIDs) are first-line therapies in the management of patients with ankylosing spondylitis. This chronic inflammatory skeletal disorder, a subtype of spondyloarthritis, is characterized by inflammatory back pain and affects young adults causing important suffering and disability. Long-term
Freneil B Jariwala et al.
Journal of the American Society for Mass Spectrometry, 25(9), 1670-1673 (2014-07-09)
We describe a diagnostic ion that enables rapid semiquantitative evaluation of the degree of oxygen contamination in the collision gases used in tandem mass spectrometers. Upon collision-induced dissociation (CID), the m/z 359 positive ion generated from the analgesic etoricoxib undergoes
Eugene R Viscusi et al.
Current medical research and opinion, 28(8), 1323-1335 (2012-06-29)
To evaluate the effects of two different doses of etoricoxib delivered perioperatively compared with placebo and standard pain management on pain at rest, pain with mobilization, and use of additional morphine/opioids postoperatively. In this double-blind, placebo-controlled, randomized clinical trial, we
Rachel Clarke et al.
The Cochrane database of systematic reviews, (2)(2), CD004309-CD004309 (2009-04-17)
Etoricoxib is a selective cyclo-oxygenase-2 (COX-2) inhibitor prescribed for the relief of chronic pain in osteoarthritis and rheumatoid arthritis, and acute pain. The drug is believed to be associated with fewer upper gastrointestinal adverse effects than conventional non-steroidal anti-inflammatory drugs
Fixed drug eruption caused by etoricoxib with tolerance to celecoxib and parecoxib.
Vanessa Ponce et al.
Contact dermatitis, 66(2), 107-108 (2012-01-12)
Marta L Capone et al.
Expert opinion on drug metabolism & toxicology, 1(2), 269-282 (2006-08-23)
Etoricoxib is a highly selective COX-2 inhibitor (coxib) approved in Europe for the treatment of osteoarthritis (OA), rheumatoid arthritis and acute gouty arthritis. Etoricoxib is an effective analgesic drug that has shown some improved efficacy versus traditional NSAIDs and it
1/2